http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1825275-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b0c198757da18cf77dfbdcef00abb70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69df0c0b3d3d93288e5c810e2eb6797e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ae079092f2e6b17a5c5110af960b6c4 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2005-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e62627a5d30c9163ca1604e2c161b355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_129ec7b9ee5f8df5f9afc7fce9191a12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de1ace0f92124584623522af8ab71719 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afaee29b006f7454ddbe043097757f2b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5df4b96362a2bb5734963fa1a6c5e959 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e011c216440227a83612431957baa904 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_111171033e7ecee8283a259911a20c96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60c8569733ce8bb732a6423bb1a2d61e |
| publicationDate | 2007-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1825275-A2 |
| titleOfInvention | Diagnosis of neurodegenerative diseases |
| abstract | The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Ace. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Ace. No. P02023); or alpha-1-antitrypsin (SwissProt Ace. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Ace. No. P51884); alpha-fibrinogen precursor (SwissProt Ace. No. P02671); IGHG4 protein (Swiss Prot Ace. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed. |
| priorityDate | 2004-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.